A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer

To evaluate the safety (including adverse events and dose-limiting toxicities [DLTs]), tolerability, pharmacokinetics and antitumor activity of the investigational MET inhibitor rilotumumab alone in patients with advanced solid tumors (Part 1) or in combination with cisplatin plus capecitabine (CX)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese journal of clinical oncology 2017-11, Vol.47 (11), p.1002-1009
Hauptverfasser:	Doi, Toshihiko, Yamaguchi, Kensei, Komatsu, Yoshito, Muro, Kei, Nishina, Tomohiro, Nakajima, Takako Eguchi, Tang, Rui, Yang, Hui, Zhang, Yilong, Jung, A Scott, Ang, Agnes, Yasui, Hirofumi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Capecitabine - administration & dosage Capecitabine - adverse effects Cisplatin - administration & dosage Cisplatin - adverse effects Disease-Free Survival Esophagogastric Junction - pathology Female Humans Male Middle Aged Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!